Sanofi highlights longer-term phase 2 extension data for its Teva-partnered inflammatory bowel disease candidate, framing the result as a key pipeline opportunity amid a tough year of clinical setbacks.
Longevity News
As Sanofi attempts to bounce back from a tough year of clinical readouts, the French pharma has touted longer-term ph...
Source: FierceBiotech - Biotech • Published: 20 Feb 2026, 04:51
Continue exploring
Related longevity signals
Longevity TechnologyInsilico revenue surges 287% in H1 2026 driven by major pharma dealsInsilico’s interim results story — a news article looking at a biotech AI company's recent financial jump and deal-driven momentum, useful for investors and industry watchers.Youtube — David SinclairHow to Exercise to Live Longer | Lifespan with Dr. David Sinclair - S2, Ep. 5Practical guidance on exercise for longer, healthier lives, comparing longevity-focused training to athletic training and key fitness metrics.Fight Aging!Bacterial Lipoic Acid Protein Ligase A Improves Mammalian Mitochondrial Function and HealthThis article previews research on using a bacterial enzyme to boost mitochondrial protein modification and overall cellular energy, framed as a potential metabolic-enhancing therapy. It invites readers curious about cross-species gene therapy approaches aimed at improving healthspan and age-related function.Nature - BiotechnologySEQURNA enhances FLASH-seq gene detection while eliminating DTT dependenceSEQURNA-focused methods article presenting a comparative benchmark of a synthetic thermostable RNase inhibitor for improved single-cell, full-length RNA-seq workflows.